Altered progranulin levels play a major role in neurodegenerative diseases, like Alzheimer’s
dementia (AD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), even in the absence of GRN mutations.
Increasing progranulin levels could hereby provide a novel treatment strategy. However, knowledge on progranulin
regulation in neurodegenerative diseases remains limited. We here demonstrate that cerebrospinal fluid progranulin
levels do not correlate with its serum levels in AD, FTD and ALS, indicating a differential regulation of its central and peripheral
levels in neurodegeneration. Blood progranulin levels thus do not reliably predict central nervous progranulin
levels and their response to future progranulin-increasing therapeutics.
Keywords: Alzheimer’s dementia, amyotrophic lateral sclerosis, biomarker, case-control study, cerebrospinal fluid,
frontotemporal dementia, GRN, progranulin, serum.
Rights & PermissionsPrintExport